Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials in Wuhan, Hubei

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden